Shea A Heilman
Overview
Explore the profile of Shea A Heilman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
51
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
tet2 and tet3 regulate cell fate specification and differentiation events during retinal development
Heilman S, Schriever H, Kostka D, Koenig K, Gross J
bioRxiv
. 2024 Dec;
PMID: 39713311
Tet enzymes are epigenetic modifiers that impact gene expression via 5mC to 5hmC oxidation. Previous work demonstrated the requirement for Tet and 5hmC during zebrafish retinogenesis. mutants possessed defects in...
2.
Heilman S, Kostka D, Schriever H, Gross J
Methods Mol Biol
. 2024 Sep;
2848:85-103.
PMID: 39240518
Recent technological advances in single-cell RNA sequencing (scRNA-Seq) have enabled scientists to answer novel questions in biology with unparalleled precision. Indeed, in the field of ocular development and regeneration, scRNA-Seq...
3.
Tiago M, Capparelli C, Erkes D, Purwin T, Heilman S, Berger A, et al.
Br J Cancer
. 2020 Jan;
122(6):789-800.
PMID: 31932756
Background: BRAF-mutant melanoma patients respond to BRAF inhibitors and MEK inhibitors (BRAFi/MEKi), but drug-tolerant cells persist, which may seed disease progression. Adaptive activation of receptor tyrosine kinases (RTKs) has been...
4.
Hartsough E, Weiss M, Heilman S, Purwin T, Kugel 3rd C, Rosenbaum S, et al.
Cell Death Dis
. 2019 Mar;
10(4):281.
PMID: 30911007
Metastatic cancer remains a clinical challenge; however, patients diagnosed prior to metastatic dissemination have a good prognosis. The transcription factor, TWIST1 has been implicated in enhancing the migration and invasion...
5.
Capparelli C, Purwin T, Heilman S, Chervoneva I, McCue P, Berger A, et al.
Cancer Res
. 2018 Aug;
78(19):5680-5693.
PMID: 30115691
MEK-ERK1/2 signaling is elevated in melanomas that are wild-type for both BRAF and NRAS (WT/WT), but patients are insensitive to MEK inhibitors. Stromal-derived growth factors may mediate resistance to targeted...